GRI Bio
2009
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Angel
LATEST DEAL TYPE
(Cancelled)
Description
Developer of therapies created to treat inflammatory diseases. The company's cell-based therapies are developed to treat liver disease and autoimmunity deficiencies by targeting the regulation of NKT cells.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 2223 Avenida De La Playa
- Suite 105
- La Jolla, CA 92037
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore GRI Bio’s full profile, request a free trial.
GRI Bio Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | Cancelled | Generating Revenue | ||||
| 1. Angel (individual) | 17-Apr-2015 | 00.000 | 00.000 | Completed | Generating Revenue |
GRI Bio Executive Team (4)
GRI Bio Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Abraham Van Wyk | GRI Bio | Board Member | 000 0000 | |
| Albert Agro Ph.D | Self | Senior Vice President of Clinical Development, Board Member and Co-Founder | 000 0000 | |
| Marc Hertz Ph.D | GRI Bio | Co-Founder, Chairman & Chief Executive Officer | 000 0000 | |
| Vipin Chaturvedi Ph.D | GRI Bio | Chief Scientific Officer, Board Member and Co-Founder | 000 0000 |
1 Former Board Member
You’re viewing 4 of 5 board members. Get the full list »